Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Session 3 – Comparing efficacy of PARP inhibition across tumour types

Rationale and development of PARPi adjuvant versus advanced or relapse: Ovary and breast examples

Date

29 Oct 2024

Session

Session 3 – Comparing efficacy of PARP inhibition across tumour types

Topics

Targeted Therapy

Tumour Site

Breast Cancer; Ovarian Cancer

Presenters

F. André, FR and I. Ray-Coquard, FR

Resources

This content is available to ESMO members and event participants.

Login